1-3 of 3
Verena Karsten, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD
Journal: Blood
Blood (2008) 112 (11): 2960.
https://doi.org/10.1182/blood.V112.11.2960.2960
Published: 2008
Journal Articles

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Francis Giles, MD, Susan O’Brien, MD, David Rizzieri, MD, Judith Karp, MD, Maureen Cooper, MD, Ghulam Mufti, MD, Bonny Johnson, MSN, Verena Karsten, PhD, Norbert Vey, MD
Journal: Blood
Blood (2005) 106 (11): 2786.
https://doi.org/10.1182/blood.V106.11.2786.2786
Published: 2005
Journal Articles

Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M).

Francis Giles, MD, David Rizzieri, MD, Judith Karp, MD, Norbert Vey, MD, Khuda Khan, MD, Ghulam Mufti, MD, Diana Hudak, Verena Karsten, PhD, Susan O’Brien, MD
Journal: Blood
Blood (2005) 106 (11): 2787.
https://doi.org/10.1182/blood.V106.11.2787.2787
Published: 2005